Products

What will AGI do for Bortezomib?

This classification denotes a proteasome inhibitor with the molecular formula C19H25BN4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 69G8BD63PP, chemically known as boronic acid, (3-methyl-1-((1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)-, (s-(r*,s*))- but generally known as bortezomib, which bears US NIH Compound Identifier 93860. European Medicines Agency schedules Bortezomib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20020. The term BORTEZOMIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 17, No. 4, 2003, List 50). World Health Organization schedules bortezomib in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule bortezomib under HS 29339990 and SITC 51577. As of Q4 2014, BORTEZOMIB remains the US FDA Preferred Term for this commodity. Bortezomib bears US NLM identifiers UMLS ID C1176309 and NCI Concept Code C1851. SMILES: O=C(NC(CC(C)C)[B](O)O)C(NC(=O)C1NCCNC1)CC1CCCCC1.